Case Report

Metastases of malignant melanoma to stomach - An unusual presentation

Arpit Jain1,*, Akanksha Jaju2, Minaal Iyer1, Ramesh Arya1, Preety Jain1
1 Dept. of Radiation Oncology, Government Cancer Hospital, MGMMC, Indore, Madhya Pradesh, India
2 Dept. of Pathology, Tata Main Hospital, Jamshedpur, Jharkhand, India

ARTICLE INFO

Article history:
Received 07-12-2018
Accepted 21-03-2020
Available online 19-08-2020

Keywords:
Malignant melanoma
Stomach metastasis

ABSTRACT

Background: Malignant melanoma has been known capable of inducing metastasis in most of the human organs. It is the most common metastatic tumor of the gastrointestinal (GI) tract; most commonly involving the small and large bowels and rectum; however, the stomach is a rare site. Gastrointestinal (GI) metastases are seldom diagnosed before death.

Case Presentation: Here we present a known and treated case of malignant melanoma of left foot, later on presenting with non-specific gastric symptoms. UGIE revealed a growth in the gastric antrum for which mucosal biopsy was performed. Histopathology revealed a poorly differentiated carcinoma and with the help of IHC obtained a conclusion of metastatic lesion of malignant melanoma.

Conclusion: Malignant melanoma of extremities warrants a thorough endoscopic evaluation for gastrointestinal metastases as > 60% cases are found to have lesions in stomach at autopsy. Hence an early diagnosis of the metastatic lesions mandate for better survival of the patients.

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/)

1. Introduction

Melanoma is a malignant tumour of melanocytes and primarily occurs in the skin. It behaves aggressively and has high rate of metastases, hence the overall prognosis is poor. 90% of all deaths related to skin cancer are related to melanoma. The regional lymphatic system accounts for two thirds of all primary metastases. Gastrointestinal melanoma is mostly the result of metastatic disease. Autopsy series report up to 60% of patients who die of metastatic melanoma having gastrointestinal (GI) involvement, with gastric involvement in approximately 20% of these cases.1,2 Patients with distant metastases of malignant melanoma have the median survival rate of 6-9 months only. We present the case of a 50-year-old female patient with a Malignant melanoma with Gastric metastases.

2. Case Report

A 47 year female was presented to our institution with complaint of a Hyperpigmented lesion over Right foot since 2 month. On examination, she was conscious, cooperative, oriented to time, place and person, vitals stable. Examination of Right foot revealed a 3cmx4cm skin lesion with blackish discolouration, irregular flat margin, non tender, no discharge, no ulceration. Full skin and ocular examinations, chest X-rays, and abdominal sonogram excluded the presence of any other clinically detectable neoplastic deposits. Patient underwent excision biopsy and Skin grafting from right thigh was done. Biopsy revealed Nodular Malignant Melanoma Clark stage V, AJCC stage pT4NxMx. Patient was planned for Prophylactic Right Inguinal Lymph Node Dissection. Biopsy shown No evidence of metastatic deposits of malignant melanoma / malignancy (s/o nonspecific reactive lymphadenitis). During the course, Patient had Laparoscopic assisted Vaginal Hysterectomy + Bilateral Salphingo-oophrectomy in the vicinity of Fibroid Uterus. Her USG findings were
cases with gastrointestinal metastasis from melanoma. (25%).
small bowel (50%), large bowel (31%), and anorectum metastasise to any organ. They are the most common anal region. They are highly aggressive tumors and can melanocytes present, as the skin, eyes, meninges, and Melanoma is commonly occurs in tissues where Metastasis to the stomach is rare, about 20% of cases with gastrointestinal metastasis from melanoma.

2. Discussion

Metastasis to the stomach is rare, about 20% of cases with gastrointestinal metastasis from melanoma. Clark level of the primary lesion often correlates with the incidence of intestinal metastasis, i.e. less than 6% for level I, 6 to 24% for level II, and more than 70% for level III or greater. Because of non-specific GI symptoms and only manifest in 1–4% of patients with metastases; such as fatigue, nausea, vomiting, abdominal cramping or pain, anemia, weight loss, melena, diagnosis is largely missed. Radiographic studies and endoscopic evaluation makes the diagnosis.

Based on Endoscopic morphological appearance gastric metastasis may be classified into three types: ulcerated melanotic nodules, submucosal masses with ulcerations, and mass lesions with necrosis and melanosis. Most common site for gastric metastases is the body and fundus, most often at the greater curvature. Immunohistochemical Confirmation of melanoma is made if the biopsies stain positively with S-100 protein and HMB-45 glycoprotein. Primary and secondary nature of gastric melanoma is difficult to establish. The criteria for a diagnosis of primary intestinal melanoma include 1) no other concurrent melanoma or atypical melanocytic lesion of the skin, 2) no evidence of extraintestinal metastatic spread of melanoma, and 3) intramucosal lesions in the overlying or adjacent intestinal epithelium.

Because of rare entity, the data supporting gastric surgery are limited beyond case reports. In a retrospective review of 124 patients with melanoma metastatic to the gastrointestinal (GI) tract, median survival in patients undergoing curative resection was 48.9 months, compared with only 5.4 months and 5.7 months in those undergoing palliative procedures and nonsurgical interventions, respectively. Even in the surgical incomplete resection of lesion, mostly patients with melanoma and GI tract metastases can have palliation of symptoms with minimal morbidity and mortality. The complete surgical resection of GI tract metastases is associated with high 5-year survival rate. Therefore, surgery should be strongly recommended for patients with melanoma and distant metastatic disease.

Adjuvant therapy for primary mucosal melanoma is unexplored and poorly understood so there are few current treatment recommendations for patients after surgical excision. In a case report, the patient received Interferon therapy for 12 months in adjuvant setting following partial gastrectomy and splenectomy of a primary gastric melanoma, and showed no evidence of disease upon UGI endoscopy two years post-operatively. Vemurafenib, a BRAF V600E inhibitor approved for the treatment of metastatic melanoma, has not been evaluated as a potential adjuvant treatment for patients with primary mucosal melanomas.

Although early clinical experience advocated melanoma to be a radioresistant tumor. However, RT can provide useful palliation for patients with unresectable metastatic melanoma. In adjuvant settings, postoperative radiation can
improve locoregional disease control, even though with potential toxicity and limited survival benefit. 

4. Conclusion
The primary malignant melanoma has an early tendency to metastasise. GI metastatic melanoma presents with non specific GI symptoms like anemia, melena, therefore it is important to perform an upper GI endoscopy to rule out metastatic disease in highly suspicious cases. Because of non specific presentation and relatively rare entity, most cases are not detected until autopsy. A primary malignant melanoma of the stomach can only be diagnosed in the absence of other lesion and the diagnosis should be confirmed by immunohistochemical staining. A multimodality approach should be targeted for an effective treatment. Resection in case of distant metastasis to stomach should be attempted if R0 resection can be achieved to increase the patient’s overall prognosis.

5. Source of Funding
None.

6. Conflict of Interest
None.

References

Author biography
Arpit Jain PG Student
Akanksha Jaju PG Student
Minaal Iyer PG Student
Ramesh Arya Professor
Preety Jain Associate Professor